Physician profile
Adam Kevin Chubak
NPI 1427477256
$5,013.34
in general payments reported to CMS, 2019-2025
26 companies · $2,143 in 2025
The $2,143 reported for 2025 was more than what 84% of Cornea and External Diseases Specialist providers received nationally (typical 2025 total: $477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.94 · 2020: $28.48 · 2021: $491 · 2022: $731 · 2023: $505 · 2024: $1,100 · 2025: $2,143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,747.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $687.27 | 2022-2025 | Idosetr, Istent Infinite, Photrexa |
| Alcon Vision LLC | $655.06 | 2019-2025 | Simbrinza, Rocklatan, Tryptyr |
| Oyster Point Pharma, INC. | $492.14 | 2022-2025 | Tyrvaya, Ryzumvi |
| Abbvie INC. | $421.71 | 2022-2025 | Durysta, Ozurdex |
| Harrow Eye, LLC | $355.06 | 2024-2025 | Vevye |
| Dompe US, INC. | $329.66 | 2021-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $318.11 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $258.86 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $257.06 | 2020-2025 | Acthar |
| Kala Pharmaceuticals, INC. | $249.34 | 2021-2022 | |
| Astellas Pharma US INC | $245.60 | 2023-2025 | Izervay |
| Bausch & Lomb Americas INC. | $156.19 | 2024-2025 | Miebo, Xiidra, Vyzulta |
| Ani Pharmaceuticals, INC. | $153.08 | 2024-2025 | Yutiq, Iluvien, Purified Cortrophin Gel |
| Rxsight INC | $63.95 | 2023-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Regeneron Healthcare Solutions, INC. | $58.37 | 2022-2023 | Eylea Hd |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $57.12 | 2024-2025 | Vabysmo |
| Biotissue Holdings INC. | $40.12 | 2022-2023 | |
| Aerie Pharmaceuticals, INC. | $30.05 | 2021 | |
| Allergan, INC. | $28.31 | 2020-2021 | |
| Amgen INC. | $27.64 | 2025 | Tepezza |
| Lumenis, INC | $26.97 | 2021 | |
| Spark Therapeutics, INC. | $24.04 | 2022 | |
| Rayner Intraocular Lenses Limited | $23.30 | 2023 | Rayone Spheric, Rayone Aspheric, Rayone Emv |
| New World Medical,INC. | $19.49 | 2024 | Clearpath, Ahmed Glaucoma Valve, Streamline |
| Apellis Pharmaceuticals, INC. | $18.97 | 2025 | Syfovre |
| Alimera Sciences, INC. | $15.87 | 2024 | Iluvien, Yutiq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Chubak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.